Atezolizumab Plus Bevacizumab With HCC and HBV Infection
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a single-arm clinical trial. The main objective is to determine the efficacy of
atezolizumab+bevacizumab therapy in patients with advanced hepatocellular carcinoma and with
chronic hepatitis B virus infection. All eligible patients will receive atezolizumab +
bevacizumab therapy.
Phase:
N/A
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Changhua Christian Hospital China Medical University Hospital Kaohsiung Medical University Chung-Ho Memorial Hospital Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taichung Veterans General Hospital Taipei Veterans General Hospital, Taiwan